West Pharmaceutical stock holds steady on 2026 earnings context
Published on 07/23/2026 at 02:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical Services, Inc. (US9523901012) remains a closely watched medical packaging name as investors weigh its latest reported operating trends against a 23 July 2026 market backdrop. The company closed 2025 with revenue of $2.89 billion, up from $2.80 billion in 2024, while diluted EPS for 2025 reached $6.09 versus $5.23 a year earlier.
Revenue reached $2.89 billion
West Pharmaceutical reported 2025 revenue of $2.89 billion, a year-over-year increase of about 3.2% from $2.80 billion in 2024. Net sales in the quarter ended 31 December 2025 were $702.2 million, compared with $705.7 million in the prior-year quarter, showing that annual growth came despite a softer fourth quarter.
Annual gross margin also remained a key marker for the stock, with 2025 operating results reflecting continued demand for drug containment and delivery systems. Diluted EPS of $6.09 in 2025 was up 16.5% from $5.23 in 2024, giving the latest full-year report a clearer earnings-growth story than the quarterly sales line alone.
EPS climbed to $6.09
That EPS gain matters because it shows West Pharmaceutical converted a modest revenue increase into stronger per-share profit growth over the 12-month period. The comparison is cleaner than a single trading session headline: revenue rose 3.2% year over year, while EPS advanced 16.5%.
For the market, the combination of $2.89 billion in 2025 sales and $6.09 in diluted EPS frames the shares as a fundamentals-driven story rather than a pure sentiment trade. The company also entered 2026 with an established base of regulated products used across injectable drug packaging and delivery applications.
2025 annual results and 2026 setup
The latest annual report gives the clearest picture of West Pharmaceuticals sales, earnings, and margin trend into 2026.
Product demand still counts
West Pharmaceutical's relevance rests on component systems for injectable medicines, where quality, consistency, and regulatory compliance matter more than quarterly headlines. That positioning explains why a 2025 revenue base of $2.89 billion and EPS of $6.09 can matter even when the latest market move is not dominated by a single event.
For investors, the product mix is important because recurring demand from pharmaceutical and biotech customers can stabilize revenue through different parts of the cycle. The 31 December 2025 quarter showed $702.2 million in sales, which provides a concrete recent reference point for the business heading into 2026.
Shares and market value
As of 23 July 2026, the share price and market capitalization were not available in the search results for this call, so the most recent body-level market reference remains the 2025 earnings base. That makes the latest annual report the clearest anchor for West Pharmaceutical stock until a fresh quoted market level is captured.
West Pharmaceutical Services, Inc. snapshot
- Company: West Pharmaceutical Services, Inc.
- ISIN: US9523901012
- Ticker: NYSE: WST
- Trading venue: NYSE
- Sector / Industry: Health Care / Health Care Equipment & Supplies
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
